Hedera Dx key facts
as of Oct 2026- Operator of a global cancer real-world data platform designed to enable molecular testing and AI-driven insights for improved cancer care outside the US.
- Hedera Dx is valued at approximately $43.0M as of Oct 2026 (last reported valuation).
- It has raised $36.8M; the latest was Early Stage VC ($16.9M) in May 2025.
- Notable investors include TA Ventures, Tesi, VSquared Ventures, GRIDS Capital, Blu Stone Management — 11 tracked in total.
- Status: Privately Held (backing).
Hedera Dx's last reported valuation, Mar 2024. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Hedera Dx: the Monday email on marks, rounds and moves
Hedera Dx funding rounds
No funding rounds for Hedera Dx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Hedera Dx
11+Membership and data by Private Market View
Hedera Dx valuation
Hedera Dx's last reported valuation was $43 million in Mar 2024. No priced round, secondary trade or fund mark has surfaced since.
Hedera Dx investors
11 investors are on record for Hedera Dx, including TA Ventures, Tesi, VSquared Ventures and GRIDS Capital.
About Hedera Dx
Operator of a global cancer real-world data platform designed to enable molecular testing and AI-driven insights for improved cancer care outside the US. The company offers a unique integration of advanced genetic testing, liquid biopsies, and real-world data, enabling healthcare providers across international markets to deliver personalized treatment options, improving patient outcomes.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2021
- Employees
- 21
- Website
- hederadx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.